The weekly litigation news digest is live. Subscribe now

IP Verse

Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative Disorders - EP3300601

The patent EP3300601 was granted to Celator Pharmaceuticals on Jan 12, 2022. The application was filed on Feb 15, 2008 under application number EP17200498A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3300601

CELATOR PHARMACEUTICALS
Application Number
EP17200498A
Filing Date
Feb 15, 2008
Status
Granted And Under Opposition
Dec 10, 2021
Publication Date
Jan 12, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKOct 12, 2022ELKINGTON AND FIFEADMISSIBLE
SANDOZOct 11, 2022KRAUS & LEDERER PARTGMBBADMISSIBLE
STADA ARZNEIMITTELOct 11, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2007076117
OPPOSITIONUS2004152632
OPPOSITIONWO2005102359
OPPOSITIONWO2007076117
SEARCHUS2004152632
SEARCHWO2005102359
SEARCHWO2007076117

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents